Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.
Africa has been attracting more diverse and innovative capital flows over recent years. The US, Europe, the Middle East, Japan, and even India are all crowding in, while China maintains its already well-established presence.